A Chinese scientist reviewing laboratory equipment

Research news

This section contains news items that were not issued as a press release.

Tuesday, 21 May 2013
AstraZeneca and Massachusetts General Hospital To Identify New Combination Therapies For Cancer AstraZeneca today announced it has entered into a collaboration with Massachusetts General Hospital (MGH) to identify patients who might benefit from unique combinations of investigational and marketed cancer therapies.
Wednesday, 24 April 2013
Alchemia Announces Multi-Target Drug Discovery Collaboration with AstraZeneca on VAST Discovery Platform Brisbane,  Australia 22 April 2013 –  Alchemia Limited (ASX:ACL), a drug discovery and development company, today announces that it has signed a multi-target, drug discovery collaboration with AstraZeneca PLC.
Monday, 22 April 2013
Horizon Discovery Announces Oncology Drug Discovery Collaboration with AstraZeneca Cambridge, UK, 22 April 2013: Horizon Discovery (Horizon) and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon’s first-in-class kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types.
Tuesday, 16 April 2013
Oxford Cancer Biomarkers announces biomarker discovery deal with AstraZeneca by Oxford Cancer Biomarkers | Apr 15, 2013
Wednesday, 3 April 2013
AstraZeneca extends drug discovery collaboration with Bayer AstraZeneca and Bayer HealthCare (Bayer) have signed a three-year extension of their compound library sharing collaboration. Under the agreement the partners provide mutual access to their compound libraries and screening technologies for selected projects. The collaboration enables each party to identify promising new starting points for their respective drug discovery research.
Monday, 11 March 2013
AstraZeneca responds to report on antimicrobial resistance Today’s report Infections and the rise of antimicrobial resistance from England's Chief Medical Officer is a powerful reminder of the global threat to public health that the rise in drug-resistant bacteria represents.
Thursday, 28 February 2013
AstraZeneca and Exco InTouch to develop real-time disease management tool for patients with chronic conditions AstraZeneca and Exco InTouch to develop real-time disease management tool for patients with chronic conditions
Tuesday, 12 February 2013
AstraZeneca and Russia’s Petrov Institute sign cancer research collaboration AstraZeneca and the N.N. Petrov Institute of Oncology, one of Russia’s leading cancer research institutions, today announced a research collaboration to identify genetic mutations in cancer patients
Monday, 11 February 2013
New IMI projects to revitalise antibiotic development New Drugs 4 Bad Bugs programme represents an unprecedented partnership between industry, academia and biotech organisations to combat antibiotic resistance in Europe.
Thursday, 7 February 2013
€196 million pan-European drug discovery platform launched Large pharmaceutical companies join forces with small and medium-sized enterprises (SMEs) and academia in an IMI-supported public private partnership (PPP) to enhance early drug discovery and so address the ever-increasing need for innovative therapeutics to tackle unmet medical needs